Study design: CheckMate 142 (CRC)

Phase 2 multi-cohort study in patients with recurrent/metastatic CRC^*,1
Primary endpoint: ORR per investigator assessment (RECIST v1.1)^a,1
Secondary endpoint: ORR per BICR^a,1
Other key endpoints: DCR, DOR, PFS, OS, and safety^a,1

*Nivolumab in combination with ipilimumab is only approved for MSI-H/d-MMR CRC that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan regimen.
^aTumor imaging assessments were performed every 6 weeks for 24 weeks and thereafter every 12 weeks until disease progression or discontinuation.
Figure adapted from Overman et al. 2018.¹

BICR, blinded independent central review; CRC, colorectal cancer; DCR, disease control rate; d-MMR, mismatch repair deficient; DOR, duration of response; IPI, ipilimumab; MSI-H, microsatellite instability high; NIVO, nivolumab; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; QxW, every x weeks; RECIST, Response Evaluation Criteria in Solid Tumors.

1. Overman MJ, et al. J Clin Oncol 2018;36:773–779.